Preclinical News and Research

RSS
Cancer drug shows promise in treating blood cell disorders

Cancer drug shows promise in treating blood cell disorders

Jackson Laboratory Cancer Center earns renewal of Cancer Center Support Grant from NCI

Jackson Laboratory Cancer Center earns renewal of Cancer Center Support Grant from NCI

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

EnGeneIC plans for Phase 2a trial of EGFR-targeted doxorubicin-packaged EDV nanocells for GBM

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Adding MM-398 to standard treatment improves survival in metastatic pancreatic cancer patients

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Preventing antibiotic side effects: an interview with Florence Séjourné, CEO, Da Volterra

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

Aerie Pharmaceuticals' Roclatan meets all clinical endpoints in Phase 2b trial

University of Maryland School of Medicine receives NIH grant to establish neuroscience research center

University of Maryland School of Medicine receives NIH grant to establish neuroscience research center

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Ligand Pharmaceuticals, TG Therapeutics sign global license agreement for IRAK-4 inhibitors

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Mersana and Merck KGaA develop next-generation antibody-drug conjugates

Researchers shown how free radicals contribute to fatty liver disease

Researchers shown how free radicals contribute to fatty liver disease

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

BioLineRx announces in-licensing of BL-1110 compound for treatment of neuropathic pain

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Bayer, Dimension Therapeutics partner to develop new gene therapy for hemophilia A

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Clinical trial shows that selumetinib drug can delay progression of metastatic uveal melanoma

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

Weizmann Institute scientists 'fingerprint' a culprit in depression and anxiety disorders

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Novogen, CanTx believe Intra-Peritoneal Trx-1 could be utilized as first-line therapy for ovarian cancer

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Pfizer and Cellectis enter into global strategic collaboration to develop CAR-T immunotherapies

Johns Hopkins to host 5th annual Graphic Medicine Conference

Johns Hopkins to host 5th annual Graphic Medicine Conference

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

New path may lead to powerful adjunctive novel therapy for PTSD treatment

New path may lead to powerful adjunctive novel therapy for PTSD treatment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.